The GLP-1 Coverage Appeal Letter That Actually Works (Template)

You did everything right — your doctor prescribed it, you met with your insurance company, and then the denial letter arrived anyway.

It's one of the most frustrating moments in healthcare, and you are not alone in facing it.

Here's the good news: a well-crafted GLP-1 appeal letter overturns denials far more often than most people realize — especially when it speaks the insurance company's language.

In this guide, you'll learn exactly what to include in a letter of medical necessity for GLP-1 drugs, how to climb the appeal ladder step by step, and you'll get a real template you can hand to your doctor today.

Specifically, you'll learn:

• Why most GLP-1 denial letters are written in a way that leaves a door open
• The exact language insurance reviewers look for in an appeal
• How to use Wegovy's cardiovascular indication as a coverage lever
• A fill-in-the-blank appeal letter template
• What to do when the appeal fails (the pivot options that actually work)

Why GLP-1 Denials Happen (And Which Ones Can Be Overturned)

Insurance companies don't deny GLP-1 drugs randomly — they deny them for specific, documented reasons.

Knowing the exact reason for your denial is the first step, because only some denial types are actually reversible through an appeal.

The Six Most Common Denial Reasons

• Plan excludes weight-loss drugs as a category — Many employer plans and most standard Medicare plans carve out "anti-obesity medications" entirely. This is a benefit-design exclusion, not a clinical decision.
• BMI or comorbidity not documented — Your chart didn't show the qualifying BMI (≥30, or ≥27 with a comorbidity) at the time of the request.
• Step therapy not completed or not documented — The plan required you to try a cheaper drug first, and there's no record of it.
• Off-label use requested — A diabetes drug (Ozempic, Mounjaro) was requested for weight loss, which is outside its FDA approval.
• Diet/lifestyle documentation missing — Most plans require documented participation in a reduced-calorie diet and exercise program, often for 3–6 months.
• Drug not on the formulary — A different GLP-1 is the plan's preferred drug, and yours wasn't requested first.

Here's the deal:

Denials from categories 2 through 6 are often reversible with the right documentation.

Category 1 — a hard benefit exclusion — is a different animal. Appeals rarely change it because the problem isn't clinical, it's contractual. We'll cover your pivot options for that scenario in Section 6.

For now, pull out your denial letter and find the specific reason code or explanation. That sentence is your roadmap.

What a Winning Appeal Letter Actually Contains

A generic letter won't move the needle. Insurance reviewers read hundreds of appeals; the ones that win are the ones that directly address each denial criterion, line by line.

Think of your appeal letter as a legal brief, not a personal plea.

The Five Elements Every Strong Appeal Must Have

1. The plan's own criteria, quoted back verbatim.

Pull the exact prior authorization criteria from your plan's coverage policy document (often called a "clinical policy bulletin"). Quote the requirement, then prove you meet it.

2. Documented BMI with the date it was measured.

Most plans require BMI ≥ 30 (obesity), or BMI ≥ 27 (overweight) with at least one qualifying comorbidity — hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. The BMI must appear in your medical chart, not just in the letter.

3. Documented comorbidities with ICD-10 codes.

Insurance reviewers respond to medical codes, not narrative descriptions. Your prescriber should list every relevant diagnosis with its ICD-10 code. This is where a lot of appeals fall flat — the condition is real, but it's not coded in the chart.

4. Diet and lifestyle program documentation.

If your plan requires 3–6 months of documented diet and exercise counseling, that documentation needs to be attached. Visit notes, referral records, or a signed attestation from your provider all work.

5. Step therapy evidence (if applicable).

If the plan required you to try a preferred drug first, include records showing you tried it, how long you took it, and why it didn't work (side effects, inadequate response, contraindication).

Bottom line:

The letter doesn't need to be long. It needs to be specific, documented, and matched one-to-one with the plan's criteria.

The GLP-1 Coverage Levers Most Patients Miss

This is the section that changes outcomes for a lot of people.

How you frame the medical necessity request matters enormously — and most patients (and some prescribers) are leaving powerful coverage levers on the table.

Lever 1: Wegovy's Cardiovascular Indication

Wegovy (semaglutide injection) carries an FDA approval that most people don't know about: it is indicated to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.

This is a game-changer for patients who have a history of heart attack, stroke, or established cardiovascular disease.

A plan that excludes weight-loss drugs may still be required to cover Wegovy when it is prescribed for cardiovascular risk reduction — because that is a cardiovascular indication, not a weight-loss indication.

If this applies to you, your prescriber should frame the request explicitly around the cardiovascular indication, with supporting documentation of the CV diagnosis.

Here's what that means for you:

If you have heart disease and obesity or overweight, "I need Wegovy for weight loss" is the wrong framing. "My patient has established cardiovascular disease and requires semaglutide to reduce major adverse cardiovascular events per its FDA indication" is the right framing.

Lever 2: The Diabetes Framing (When It Applies)

Coverage for GLP-1 drugs for type 2 diabetes is near-universal across commercial plans and Medicaid.

If you have a type 2 diabetes diagnosis, a request for Ozempic (semaglutide) or Mounjaro (tirzepatide) framed around diabetes management is a dramatically easier path than a weight-loss request for Wegovy or Zepbound.

This isn't a workaround — it's using the correct drug for the correct approved indication. Your prescriber determines which drug and which indication is appropriate for your situation.

Lever 3: Comorbidities That Unlock the BMI-27 Tier

Many patients assume they don't qualify because their BMI is between 27 and 29. But most plans cover GLP-1s at BMI ≥ 27 when at least one weight-related comorbidity is documented.

Qualifying conditions typically include:

• Hypertension
• Type 2 diabetes
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Established cardiovascular disease

If any of these appear anywhere in your medical record, they need to appear — with ICD-10 codes — in the prior authorization request and the appeal letter.

For more detail on exactly what prior authorization requires, see our full guide: GLP-1 Prior Authorization: The Exact Requirements (and How to Meet Them).

The Letter of Medical Necessity Template

Below is a template your prescriber can adapt and sign. The language is intentionally clinical — insurance reviewers need medical framing, not personal stories.

Print this, bring it to your next appointment, and ask your provider if it applies to your situation.

[PRESCRIBER LETTERHEAD]

Date: [Date]

To: [Insurance Company Name], Appeals and Grievances Department

Re: Medical Necessity Appeal — [Patient Name], DOB [Date of Birth], Member ID [Member ID]

Drug Requested: [Drug Name, e.g., Wegovy (semaglutide injection) 2.4 mg weekly]

Denial Reference Number: [From your denial letter]

Dear Medical Director:

I am writing to appeal the denial of prior authorization for [Drug Name] for my patient, [Patient Name]. I am requesting reversal of this denial on the basis of medical necessity as defined by your plan's coverage policy.

Patient Clinical Summary:

My patient is a [age]-year-old [male/female/person] with a documented BMI of [X] as measured on [date], which meets your plan's criterion of [BMI ≥ 30 / BMI ≥ 27 with comorbidity]. [He/She/They] has the following documented weight-related comorbid conditions:

• [Condition 1, ICD-10: X00.0]
• [Condition 2, ICD-10: X00.0]
• [Add all applicable conditions]

Response to Prior Treatment:

This patient has participated in a structured, reduced-calorie diet and increased physical activity program as documented in visit notes dated [date range]. [If step therapy applies: The patient previously completed a trial of [drug name] from [date] to [date], which was discontinued due to [reason — inadequate response / adverse effects / contraindication], as documented in the attached records.]

Medical Necessity Rationale:

[Choose the applicable framing — delete the others]

For weight loss / obesity indication: [Drug Name] is FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. This patient meets both criteria. Continued obesity-related comorbidities place this patient at significant risk for [cardiovascular events / progression of diabetes / worsening sleep apnea — select applicable]. Pharmacologic intervention is medically necessary as an adjunct to diet and exercise.

For cardiovascular indication (Wegovy only): Wegovy (semaglutide 2.4 mg) is FDA-approved to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and obesity or overweight. This patient carries a documented diagnosis of [cardiovascular disease diagnosis, ICD-10 code] and a BMI of [X]. This request is submitted under the cardiovascular indication, not solely a weight-management indication.

For type 2 diabetes (Ozempic or Mounjaro): This patient carries a confirmed diagnosis of type 2 diabetes mellitus (ICD-10: E11.X) and requires improved glycemic control. [Drug Name] is FDA-approved for this indication. Current HbA1c of [X]% as of [date] demonstrates inadequate control with current regimen.

Supporting Documentation Attached:

• Relevant chart notes documenting BMI, diagnoses, and comorbidities
• Diet and lifestyle program documentation
• Prior treatment records (if step therapy required)
• Lab results (HbA1c, lipid panel, as applicable)

I am available for a peer-to-peer review call with your medical director at your earliest convenience. Please contact my office at [phone number] to schedule.

Thank you for your reconsideration.

Sincerely,

[Prescriber Name, Credentials]
[NPI Number]
[Practice Name, Address, Phone]

For more on what to do if the first denial stands, read: Wegovy Prior Authorization Denied? How to Overturn It (2026).

The Appeal Escalation Ladder

One appeal submission is rarely the end of the road. Insurance companies have a defined escalation process — and each rung gives you another shot.

Here's the full ladder:

Step 1: Internal Appeal #1

Submit the letter of medical necessity above, with all supporting documentation, within the timeframe shown on your denial letter (typically 30–180 days — read yours carefully).

Keep a copy of everything you send and document the date and method of submission.

Step 2: Peer-to-Peer Review

This is often the highest-value step and the one most patients don't know to ask for.

Your prescriber calls the insurance company's medical director directly — doctor to doctor — and makes the clinical case in real time.

Ask your prescriber's office explicitly: "Will you request a peer-to-peer review?" Many denials are overturned at this stage before a formal second appeal is even needed.

Step 3: Internal Appeal #2

If Step 1 is denied and peer-to-peer review doesn't resolve it, submit a second internal appeal — ideally with any new documentation that wasn't available the first time (updated lab results, a specialist letter, additional comorbidity coding).

Step 4: External Independent Review

If internal appeals are exhausted, you have the right to an external review by an Independent Review Organization (IRO) — a neutral third party with no financial relationship to your insurer.

This is where benefit-exclusion versus medical-necessity disputes often get decided. For clinical denials (as opposed to hard exclusions), external review outcomes can favor the patient.

Your denial letter is legally required to explain how to request external review. Find that section and follow it exactly.

When the Appeal Won't Work — Your Pivot Options

Some denials are not reversible through the appeal process, and it's worth being honest about that.

If your plan excludes all anti-obesity medications as a benefit category — a hard exclusion — the internal appeal process is unlikely to change it, because the problem is not clinical. It's contractual.

So what do you do?

You pivot to one of these paths:

Option A: Cash Self-Pay Programs

Several manufacturers offer self-pay pricing that doesn't require insurance at all (as of June 2026 — verify current availability):

These programs do not require insurance approval. They do have dose limits and expiration dates, so verify current terms before you count on them.

Option B: The Medicare GLP-1 Bridge (Medicare Patients)

Standard Medicare does not cover GLP-1s for weight loss. But starting July 1, 2026, eligible Part D members can access the Medicare GLP-1 Bridge — a limited demonstration program that provides Wegovy, Zepbound, Mounjaro (injectable), Ozempic, the Wegovy pill, and Foundayo at approximately $50/month after deductible.

This is a time-bound demonstration, not permanent coverage, and not every plan or person qualifies. See our full breakdown at /medicare-bridge and verify your specific plan's participation.

Option C: Manufacturer Savings Cards (Commercial Insurance Only)

If you have commercial (employer or marketplace) insurance — not Medicare, Medicaid, or Tricare — manufacturer savings cards can dramatically reduce your out-of-pocket cost even if your plan's coverage is partial. Foundayo's savings card brings the cost to as little as $25/month for eligible commercial patients.

The #1 reason savings cards fail: the patient has Medicare or Medicaid. Federal law prohibits using savings cards with government plans.

Option D: Reframe the Indication

As covered in Section 3, if a different indication applies to your medical situation — cardiovascular risk reduction with Wegovy, or type 2 diabetes management with Ozempic or Mounjaro — working with your prescriber to frame the request around that indication may open a coverage path that a pure weight-loss framing doesn't.

For the full picture on what to do when insurance won't cover your GLP-1, see: Insurance Won't Cover Wegovy for Weight Loss? Do This.

If you're on Medicaid, coverage depends heavily on your state — 13 states have confirmed GLP-1 weight-loss coverage as of mid-2026, while several others are cutting it. Check your state's status at /medicaid.

Your Next Move

Getting a GLP-1 denial overturned isn't about luck — it's about giving the insurance reviewer exactly what they need to say yes: documented criteria, clinical language, and the right framing for your specific situation.

Start by pulling your denial letter, identifying the exact reason code, and bringing this template to your prescriber's office this week.

And if the appeal doesn't go your way, there are more paths to affordable GLP-1s than most patients realize — we track every legitimate one.

What's the specific denial reason on your letter? Share it in the comments and we'll point you to the most relevant resources for your situation.